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Abstract
Background: A high level of genetic stability has been formerly identified in segments of the gene
coding for the liver stage antigen-3 (LSA-3), a subunit vaccine candidate against Plasmodium
falciparum. The exploration of lsa-3 polymorphisms was extended to the whole sequence of this
large antigen in 20 clinical isolates from four geographical areas; Senegal, Comoro islands, Brazil and
Thailand.
Methods: The whole 4680 bp genomic sequence of lsa-3 was amplified by polymerase chain
reaction and sequenced. The clinical isolate sequences were aligned on the sequence of the
laboratory reference P. falciparum strain 3D7.
Results: The non-repeated sequence of lsa-3 was very well conserved with only a few allelic
variations scattered along the sequence. Interestingly, a formerly identified immunodominant
region, employed for the majority of pre-clinical vaccine development, was totally conserved at the
genetic level. The most significant variations observed were in the number and organization of
tetrapeptide repeated units, but not in their composition, resulting in different lengths of these
repeated regions. The shorter repeated regions were from Brazilian origin. A correlation between
the geographical distribution of the parasites with single nucleotide polymorphisms was not
detected.
Conclusion: The lack of correlation between allelic polymorphisms with a specific transmission
pressure suggests that LSA-3 is a structurally constrained molecule. The unusual characteristics of
the lsa-3 gene make the molecule an interesting candidate for a subunit vaccine against malaria.
Background
The human malaria parasite Plasmodium falciparum is
responsible for 300-500 million clinical cases and 1-2
million deaths every year mainly among young African
children [1]. The incidence of malaria among travellers
from non-endemic areas is on the rise [2]. The emergence
and spread of resistances against anti-malarial drugs
makes the development of a vaccine an urgent need.
Naïve volunteers immunized with radiation-attenuated
sporozoites [3], the form of the parasite injected in the
host by a mosquito bite, but not killed parasites, were pro-
tected from a challenge with wild-type parasites. This
observation suggests that the partial intra-hepatic devel-
opment of the parasite was necessary to confer protection
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against the pre-erythrocytic (PE) stages of P. falciparum as
it has been further verified with recently developed genet-
ically attenuated parasites [4].
A subset of twenty parasite antigens expressed during the
PE stages were identified by screening an expression
library of P. falciparum with sera from Europeans living in
endemic areas that followed a continuous prophylactic
treatment against the pathogenic blood stages of the par-
asite [5]. The liver stage antigen-3 (LSA-3) was further
selected using discriminating sera of volunteers immu-
nized by radiation-attenuated parasites that were pro-
tected against an experimental challenge versus sera from
volunteers receiving over-irradiated parasites who were
not protected. LSA-3 is a molecule of 1558 amino acids in
the strain 3D7 of P. falciparum, which includes a majority
of non-repetitive sequences and a block of tetrapeptide
repeats organized in a-helices [6,7]. These repeats contain
the motif E-E-X-hydrophobic amino acid-E-E shared by
three other parasite antigens; RESA, Pf11.1 and Ag332 [8]
and recognized by a human monoclonal antibody devel-
oped against a parasite of Liberian origin [9]. LSA-3 is the
only molecule of this cross-reacting family of glutamic
acid dipeptides-containing antigens that is specifically
expressed during the PE stages, both on the surface of spo-
rozoites and in the parasitophorous membrane in the
liver cells [7]. The immunogenicity and protective poten-
tial of LSA-3 was established by a series of murine and pri-
mate pre-clinical studies [7,10-12]. Its antigenicity was
demonstrated by several immuno-epidemiological stud-
ies in malaria-exposed populations [13]. The implication
of LSA-3 in the immune response against the PE stages
was demonstrated in a murine model where intra-hepatic
granulomas of immune cells developed both around the
liver forms and around LSA-3 peptide-coated beads that
were injected in the portal vein of LSA-3 immunized ani-
mals [14]. Recently, an early serodiagnosis test at the PE
stages of P. falciparum infection was developed with a
recombinant LSA-3 enzyme-linked immunosorbent assay
in Burmese patients [15], and in French troops stationed
in Africa (Pradines, Rogier, personal communication).
The antigens polymorphism represents a major hurdle in
the development of vaccines against malaria [16]. Natural
epitope polymorphisms require to include all known alle-
les in a given vaccine formulation and, in addition can
alter the nature of the immune response against the origi-
nal epitope. Indeed, CSP-specific CD4+ T cells shifted
their cytokine production from IFN-γ towards the immu-
nosuppressive interleukin-10 in presence of the variant
epitope called an altered peptide ligand (APL) [17].
Owing to the vaccine potential of LSA-3, the genetic stabil-
ity of this antigen in clinical isolates from different areas
of the world was investigated. The former results obtained
on an immunodominant region of LSA-3 were confirmed
in this study [7,10] and extended to the whole genetic
sequence of lsa-3. Strikingly, this molecule appears to be
strongly conserved in samples from such distant areas as
South America, Africa and South East Asia. The only sig-
nificant variations consisted in the number of tetrapep-
tides repeated units, but not in their composition. No
obvious geographical pattern of allelic diversity in the lsa-
3 gene was identified. This characteristic adds arguments
in favour of the usefulness of this molecule in a subunit
vaccine against malaria.
Methods
Genomic material from Plasmodium falciparum strains
Genomic DNA from field isolates of the parasite blood
stages was obtained by extraction with the Qiamp DNA
blood minikit (Qiagen, USA) on blood samples received
from Dielmo in Senegal (n = 7), Brazil (n = 5), Comoro
islands (n = 6) and Thailand (n = 2). Nucleotide sequence
data reported in this paper are available in the GenBank™,
EMBL and DDBL databases under the accession numbers
GQ222688-GQ22707.
PCR amplification, cloning and sequencing of lsa-3
The complete sequence of lsa-3 was obtained by a set of six
PCR amplifications (Figure 1) with the corresponding
PCR primer pairs (Table 1) designed after the lsa-3
sequence found in the strain K1 of P. falciparum (GenBank
accession number: AJ007010) [7]. The sequences of the
PCR primers originally designed to amplify lsa-3 from the
strain K1 matched the sequence in the strain 3D7 (Gen-
Bank accession number: AE001424) [18]. The PCR reac-
tions were performed on genomic DNA with 2,5 units of
AmpliTaq DNA polymerase (Roche, USA) in a final vol-
ume of 50 μL of a buffer solution containing 1,5 mM of
MgCL2, 800 μM of dNTPs and 500 nM of primers. The
cycling programme was; 94°C/2 min, [(94°C/15 sec,
57°C/30 sec, 72°C/1 min) × 35], 72°C/2 min, on a PTC-
200 thermal cycler (MJ Research). Two sets of PCR ampli-
fications were serially completed on the same samples to
prevent ambiguities introduced by the Taq polymerase
and thereby confirm any observed mutation. The PCR
fragments were purified by electrophoresis in an agarose
gel and extracted with the Qiaquick gel extraction kit (Qia-
gen) before to be introduced in the sequencing plasmid
vector pCR4-TOPO. Chemically competent Escherichia coli
Top 10 bacteria were transformed with an aliquot of the
reaction according to the manufacturer instructions (Inv-
itrogen, USA). Plasmids from recombinant bacteria were
prepared with the QIAprep miniprep kit (Qiagen, USA)
and analysed by restriction enzymatic digestion. The frag-
ment-containing plasmids were sent to a genomics com-
pany for sequencing (Cogenics, Meylan, France).Malaria Journal 2009, 8:247 http://www.malariajournal.com/content/8/1/247
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Analysis of lsa-3 sequences
The mutations observed after the two sets of PCR amplifi-
cations were considered as true polymorphisms whereas
mutations observed after a single set of PCR were consid-
ered as errors introduced by the Taq polymerase in the
amplification step. The sequencing traces were aligned
with the SeqMan software (Lasergene, Germany). The
derived nucleic and protein sequences were aligned by the
MegAlign software (Lasergene, Germany) using the clus-
talW algorithm and compared to the lsa-3 sequence of the
P. falciparum laboratory strain 3D7 believed to have origi-
nated from Africa [18]. Sequences coding for repeats in
the molecule were further aligned manually (Additional
file 1). The sequences corresponding to the short intron
(Figure 1) were ignored because of the difficulty to relia-
bly amplify this region composed by long strings of A and
T nucleotides. Numerations of nucleic and protein
sequences were done according to the sequence of lsa-3
mRNA and LSA-3 protein of the P. falciparum strain 3D7.
Results and discussion
Amplification of the lsa-3 gene
The amplification of the gene was achieved by using PCR
primers based on the sequence of the previously cloned
and fully sequenced lsa-3 gene from the strain K1 of P. fal-
ciparum [7]. A scheme of the DNA sequence of lsa-3 in the
generic strain 3D7 is shown in the Figure 1 with the loca-
tion and size of the six fragments amplified. The primer
pairs (Table 1) were fully operative on the 20 clinical iso-
lates analysed, even with a stringent annealing tempera-
ture of 57°C in the PCR programme.
Polymorphism of lsa-3 at the genetic and protein levels in 
the non-repeated regions
The sequences of the full length of the lsa-3 gene from the
20 clinical isolates were compared with the published
sequence of the laboratory strain 3D7 [18]. The number
of punctual mutations in the sequence coding for the large
non-repeated regions of the molecule among the 20 iso-
lates was remarkably low with only 15 single nucleotide
polymorphisms (SNPs) out of 3444 base pairs (Figure 2
and Additional file 2). Five of these were synonymous
mutations (33%) whereas 10 were non-synonymous
resulting in amino acid changes. This was not unexpected
because the full sequencing of lsa-3  in the laboratory
strain K1 of Thai origin reported six SNPs along the same
sequence with two synonymous mutations (33%) [7].
Moreover, the complete conservation at the genetic level
of a sequence coding for an immunodominant region of
LSA-3 (lsa-3410-775) that was previously observed in 27
samples from diverse geographical areas [10] was con-
firmed in the samples analysed in this study. These fre-
quencies are much lower than in other P. falciparum
vaccine candidates, such as for example PfAMA1 with 130
Diagrammatic representation of the P. falciparum lsa-3 gene Figure 1
Diagrammatic representation of the P. falciparum lsa-3 gene. The intron is shown as a single line. Sequences coding for 
the repeated regions I, II and III of the LSA-3 protein are depicted as hatched boxes in exon 2. Fragments amplified by PCR for 
sequencing are shown below.
500 1000 1500 2000 2500 3000 3500 4000 4500 0
5T
Repeats I/II
Repeats I/II
6.1-6.2
C1-C2
Repeats III
3T
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Scale (bp)
Table 1: Primer pairs used to amplify the lsa-3 gene in clinical isolates genomic material.
PCR fragment Primer forward (5' 3') Primer reverse (5' 3') PCR length a
5T GTTAGAAAATGACAAATAGTAATTAC GTGTTGTTGTTCTTGTTGAACAC 829
Repeats I/II (PCR1) GTAAAAAGTGTTCAACAAGAAC TTCCTCAGTTTCGATACCACC 1188
Repeats I/II (PCR2) GAAAATATTTTGGAGGAAAGTCAAG ACTGTCCTTTATTTCCTCAGTTTCG 1251
6.1-6.2 GGTATCGAAACTGAGGAAATAAAGG CATAGCAGGAACATCAACATCCAC 789
C1-C2 GAAACTGTAACTGAACATGTAGAAC CTTCAAGATCTTTTAAATCAGATAC 745
Repeats III GATGTCGAAGAAGACAAGATCG CTTTTCAATGCGTTTCTCTTTTTGG 855
3T GGTGAAGACAAAGATGAAGTTATAG GCAATTTTTTATTTTGATTTTTGCGTTC 665
a, PCR fragment length in base pairs according to the lsa-3 nucleotide sequence in P. falciparum strain 3D7.Malaria Journal 2009, 8:247 http://www.malariajournal.com/content/8/1/247
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non-synonymous mutations out of 1,800 base pairs in 13
Indian samples [19]. The silent mutation a3882c identi-
fied on 12 out of 18 Gambian isolates in a sequence cod-
ing for la90 [20], a peptide recognized by the molecule of
the histocompatiblity complex HLA-B53 that is associated
with resistance to severe malaria in West Africa was not
observed in this study.
The singleton variations could be classified in three cate-
gories (Figure 2). Firstly, singletons observed in a single
isolate as a157g in Com 119, t247c in Sen 5522, a1778g
in Sen 5514, g2629a in Sen 5505, and c3556t in Sen 5510.
Secondly, singletons or group of singletons that were asso-
ciated with a group of isolates; a1957g, c1998t and
g3108a in Bra 1905 and Bra 1884, g2136a in Sen 5510,
Sen 5514, Tha 28, Tha 52 and the laboratory strain K1,
c4340t in Brazilian isolates 1915, 1882 and 1853. Thirdly,
singletons seen in most of the isolates compared to the
generic sequence of the strain 3D7, a237t, g2144a,
g3108a, a3786g and t4656a. A deletion of the codon gaa
(lsa-34121-4122) was detected in isolates Bra 1905, Bra 1884
and Sen 5522.
The very low number of SNPs in lsa-3 compared to most
of the actual malaria candidate vaccines, mainly expressed
during the asexual blood stages (ABS), might relate to the
PE expression of the protein. The PE antigens are likely
less exposed to immunological pressure; Firstly, because
of the tremendously lower numbers of PE schizonts as
compared to ABS schizonts [21]. Secondly, once injected
in the host blood by an infected mosquito, the sporo-
zoites infect liver cells within a few minutes were they
expand and mature inside hepatocytes hidden from anti-
bodies. Finally, the liver maintains a tolerogenic response
towards incoming harmless antigens [22] that might
favour the development of the parasite.
However, the sequence of msp-3 coding for the C-terminal
region of the merozoite surface protein-3, which is
expressed on the surface of merozoites in ABS that are
more exposed to immune surveillance, was also remarka-
bly conserved in the same clinical isolates [23]. These
results suggest that, independently of the stage of expres-
sion, mechanisms such as structural constraints may drive
the genetic stability observed in these antigens and act
against the occurrence of mutations.
Polymorphism of the repeated regions of lsa-3
The amplification of the sequence coding for the repeated
contiguous regions I and II of LSA-3 showed considerable
Nucleotide and protein sequences of LSA-3 from P. falciparum clinical isolates Figure 2
Nucleotide and protein sequences of LSA-3 from P. falciparum clinical isolates. The nucleotide sequence of the 
codons from the reference strain 3D7 with the positions of mutated bases in bold are shown on top. The mutated codons for 
each clinical isolates are shown below. Sequences corresponding to the repeated sequences I (LSA-3667-834), II (LSA-3835-1758) 
and III (LSA-33910-4047) are omitted and represented by three dots. The corresponding amino acid changes resulting from non-
synonymous mutations are shown below amino acid residues found in the reference strain 3D7. Identical codons and amino 
acid residues are represented by hyphens. del denotes a deletion of a codon and the corresponding amino acid.
Nucleotidic sequences
157 191 237 247 1778 1957 1998 2136 2144 2629 3108 3556 3786 4120 4340 4656
3D7 ACA GCT GTAT TG ... GAC ACT CTCG AG AGT GGG GAGC AT AAA ... GAA GCAA G T
Sen 5522 --- --- GTTC TG ... --- --- --- --- AAT --- GAA --- AAG ... del --- AGA
Sen 5533 --- --- --- --- ... --- --- --- --- --- --- --- --- AAG ... --- --- ---
Sen 1952 --- --- --- --- ... --- --- --- --- --- --- GAA --- AAG ... --- --- AGA
Sen 5505 --- --- GTT --- ... --- --- --- --- --- AGG --- --- AAG ... --- --- AGA
Sen 5510 --- --- GTT --- ... --- --- --- AAG AAT --- --- TAT AAG ... --- --- AGA
Sen 5514 --- --- --- --- ... CGC --- --- AAG AAT --- --- --- AAG ... --- --- ---
Sen 5517 --- --- --- --- ... --- --- --- --- --- --- --- --- AAG ... --- --- ---
Bra 1905 --- --- GTT --- ... --- GCT CTT --- --- --- GAA --- AAG ... del --- AGA
Bra 1915 --- --- --- --- ... --- --- --- --- AAT --- --- --- AAG ... --- GTAA G A
Bra 1884 --- --- --- --- ... --- GCT CTT --- --- --- GAA --- AAG ... del --- AGA
Bra 1882 --- --- --- --- ... --- --- --- --- AAT --- --- --- AAG ... --- GTAA G A
Bra 1853 --- --- --- --- ... --- --- --- --- AAT --- --- --- AAG ... --- GTAA G A
Com 119 GCA --- GTT --- ... --- --- --- --- AAT --- --- --- AAG ... --- --- AGA
Com 151 --- --- GTT --- ... --- --- --- --- --- --- GAA --- AAG ... --- --- AGA
Com 176 --- --- GTT --- ... --- --- --- --- --- --- GAA --- AAG ... --- --- AGA
Com 183 --- --- GTT --- ... --- --- --- --- AAT --- --- --- AAG ... --- --- AGA
Com 545 --- --- GTT --- ... --- --- --- --- --- --- GAA --- AAG ... --- --- AGA
Com 524 --- --- --- --- ... --- --- --- --- AAT --- GAA --- AAG ... --- --- ---
Tha 28 --- --- --- --- ... --- --- --- AAG AAT --- GAA --- --- ... --- --- ---
Tha 52 --- ACT --- --- ... --- --- --- AAG AAT --- GAA --- AAG ... --- --- AGA
K1 --- ACT --- --- ... --- --- --- AAG AAT --- GAA --- AAG ... --- --- AGA
Amino acid sequences
53 64 69 83 593 653 666 712 715 877 1036 1186 1262 1374 1447 1552
3D7 T A V L ... D T L E S G E H K ... E A S
Clin.Isol. A D - - ... G A - K N R - Y - ... del V RMalaria Journal 2009, 8:247 http://www.malariajournal.com/content/8/1/247
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size variation ranging from 264 nucleotides in the isolate
Bra 1853 to 1800 in the K1 strain, respectively (Figure 3).
The figure 4 illustrates the corresponding number of
tetrapeptide repeats ranging from 22 in the sample Bra
1853 to 150 in the laboratory strain K1.
The region I is composed of 14 tetrapeptides in the strain
3D7. Deletions of six tetrapeptides in isolates Bra 1915,
Bra 1882 and Bra 1853 and insertions of two tetrapeptides
in Com 524 were detected (Additional file 1). The poly-
morphism E253G was observed in all strains but not in
the strain 3D7. This suggests that the glutamic acid residue
at the position 253 of the LSA-3 protein in the strain 3D7
could result from an artificially introduced mutation dur-
ing the sequencing process of the gene.
The region II contributes the most to the repeat length het-
erogeneity between isolates (Figures 3 and 4, Additional
file 1). Unique tetrapeptides were identified in isolates
Sen 5522 (DDGS, VASS, IASS, VDES, IDSS), Sen 5514
(VVEN), Com 119 (VAED, VAEK) and Com 524 (VVPS).
The region III show little variations compared to the
sequence of 3D7 composed of eleven tetrapeptides with
only a tetrapeptide deletion in all strains but Tha 28 (no
deletion) and Com 119 (two deletions) (Additional file
1). The repeats composition were identical in all strains
apart from two polymorphisms in Sen 5533 changing a
tetrapeptide IDED to a unique IEEN.
The results show that apart from some unique repeats in
region II, the composition of most of the tetrapeptide
repeats was identical in all strains but solely their number
and organisation in the repeated regions varied (Figures 3
and 4, Additional file 1).
Overall, twenty-two SNPs scattered along the lsa-3
sequence (Figure 2 and Additional files 1 and 2) were
identified. The polymorphisms in the repeated regions of
lsa-3 consisted mainly in insertions, deletions and/or reor-
ganizations of sequences coding for the same tetrapeptide
units in LSA-3. Although the number of clinical isolates
analysed did not allow to draw definitive conclusions, the
samples from Brazil seemed to contain the shorter
repeated regions whereas samples originating from Thai-
land with the laboratory strain K1 contained the largest
(Figure 4). At a time when the polymorphism of LSA-3
had not yet been investigated, it is this particular criterion,
of longer length, that led us to choose K1 for molecular
characterization of the gene. Hence, the particular length
of LSA-3 in K1 is not a surprise, and results now indicate
that this size is only due to repeats duplications.
The strong disparity in the number of repeats in region I
and II suggest that the length of this area of the molecule
is dispensable for the fitness of the parasite. The repetitive
organization of these sequences usually produces B cell
epitopes that are immunodominant in other genes, as
compared to non-repeated regions. It has been proposed
that repeated sequences might act on the intensity and
quality of the immune response [24] and thus contribute
to the immune escape of the parasite. A putative escape
mechanism could be to divert the immune response from
protective epitopes towards these repeated regions of the
parasite antigens. However, in the case of LSA-3, detailed
immunological studies in hyperendemic areas revealed
that B-cell epitopes defined in non-repeated regions were
lsa-3 repeats-coding fragments amplified by PCR showing the  size polymorphism of the repeated region I and II Figure 3
lsa-3 repeats-coding fragments amplified by PCR 
showing the size polymorphism of the repeated 
region I and II.
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as much the target of antibodies as the repeat blocks [13].
Hence, in contrast to other genes encoding repeats and
particularly Glu-rich repeats, the Glu-rich block of LSA-3
does not seem to be immunodominant. The presence of
such repeats in several malarial antigens and the network
of cross-reactivity they generate across those molecules
have been frequently stressed, however their functions
remain poorly understood.
Conclusion
LSA-3 is a highly conserved antigen among clinical iso-
lates of P. falciparum originating from diverse geographi-
cal areas. There is a significant allelic polymorphism
solely in the number and organization of the repeated
tetrapeptide units. These results question the functionality
of the repeated regions of LSA-3 and other genes contain-
ing similar structures, and their interaction with the
immune system. The paucity of single nucleotide poly-
morphisms is a positive feature for the development of
LSA-3 as a deployable subunit vaccine candidate against
malaria for populations living in endemic areas as well as
for naïve travellers. However, the effect of LSA-3 repeats
length on the host immune response should be carefully
analysed and the vaccine candidate tailored accordingly.
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